Welcome to our dedicated page for JOHNSON & JOHNSON SEC filings (Ticker: JNJ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Johnson & Johnson filings document the regulatory record for a New Jersey healthcare company with Innovative Medicine and MedTech operations. Recent 8-K reports cover sales and earnings releases, dividend actions, annual meeting voting results and other material corporate events.
The company’s proxy materials describe board elections, executive compensation votes and shareholder governance matters. Its exchange-registered securities include JNJ common stock and multiple NYSE-listed notes with maturities extending across the company’s long-term debt profile.
Johnson & Johnson VP Corporate Controller Robert J. Decker reported multiple equity compensation transactions. On February 15, 2026, he received a grant of 4,871 employee stock options and 700 restricted share units (RSUs) under the company’s Long-Term Incentive Plan, each RSU representing the right to one common share upon vesting.
On February 13 and 15, 2026, previously awarded RSUs and performance share units vested and were converted to common stock through several derivative exercises coded “M.” To cover tax obligations on these vestings, a portion of the resulting shares (including amounts coded “F” at prices around $243.45–$244.55) was withheld and disposed of as tax-withholding transactions, not open-market sales. After these transactions, he reported direct ownership of common stock plus additional indirect holdings through an ESOP and 401(k) plan.
Johnson & Johnson executive John C. Reed, EVP of Innovative Medicine R&D, reported multiple equity compensation transactions. He exercised employee stock options and restricted share units into common stock and received new awards of 49,382 employee stock options and 3,546 restricted share units under the company’s long-term incentive plan.
On February 17, 2026, he sold 53,931 shares of common stock in open-market transactions at a reported price of $243.0000 per share, following option exercises at lower exercise prices. The filing also shows shares withheld at $243.4500 per share to cover tax liabilities upon RSU vesting, and his remaining common stock holdings are reported as directly owned.
Johnson & Johnson EVP and Chief Legal Officer Elizabeth Forminard reported multiple equity compensation moves. On February 15, she received 27,076 employee stock options and 1,944 restricted share units at a stated price of $0.0000 per unit. Around the same time, previously granted RSUs and performance share units vested and converted into common stock, while several hundred shares were withheld at about $243–$245 per share to cover tax obligations.
Johnson & Johnson executive Jennifer L. Taubert reported multiple equity transactions tied to long-term incentive awards. On February 13, 2026, she acquired common stock through the vesting and conversion of 1,302 Restricted Share Units and 27,412 Performance Share Units. Shares totaling 409 and 13,547 were withheld at prices of $244.55 per share to cover related tax obligations.
On February 15, 2026, she received new grants of 54,869 employee stock options and 3,940 Restricted Share Units under the company’s Long-Term Incentive Plan, and additional RSUs vested into 1,594 and 1,847 common shares. To satisfy taxes on these vestings, 816 and 945 shares were withheld at $243.45 per share. After these transactions, she continued to hold a substantial number of Johnson & Johnson common shares directly.
Timothy Schmid, EVP and Worldwide Chair, MedTech at Johnson & Johnson, reported a series of equity award exercises, sales, and new grants. He sold 22,623 shares of Common Stock in open-market transactions around $244 per share on February 18, 2026 after exercising employee stock options.
Earlier in February, Schmid acquired shares through the vesting and conversion of Restricted Share Units and Performance Share Units, with some shares withheld to cover taxes as noted in the Long-Term Incentive Plan footnotes. On February 15, 2026, he received new grants of 35,489 employee stock options and 2,548 Restricted Share Units.
Following these transactions, Schmid directly held 26,769 shares of Common Stock, plus indirect holdings of 745 shares via a 401(k) and 46 shares via an ESOP as of the plans’ most recent reporting date.
JOHNSON & JOHNSON CEO and Chairman Joaquin Duato reported multiple equity transactions related to the company’s long-term incentive plan. On February 15, 2026, he received a grant of 131,734 employee stock options and 9,459 restricted share units, each representing the right to receive one share of common stock upon vesting.
Across February 13 and 15, 2026, previously awarded RSUs and performance share units vested and were converted into common stock through several exercises coded “M”. In connection with these vestings, common shares coded “F” were withheld at prices around $243.45–$244.55 per share to satisfy tax obligations. Duato also reports indirect holdings of 998 common shares through a 401(k) plan and 30,852 shares held by his spouse.
Johnson & Johnson executive Vanessa Broadhurst, EVP of Global Corporate Affairs, reported several equity transactions. On February 17, 2026, she completed an open-market sale of 6,197 shares of Common Stock at a weighted average price of $243.39 per share, leaving her with 23,003 shares of common stock held directly.
On February 13 and 15, 2026, previously granted Restricted Share Units (RSUs) and Performance Share Units (PSUs) vested and were converted into common shares, with a portion of those shares withheld to cover tax obligations. The filing also shows new equity awards under Johnson & Johnson’s Long-Term Incentive Plan, including 14,405 employee stock options and additional RSUs that generally vest in three equal annual installments beginning on the first anniversary of their grant dates.
Fidelity Brokerage Services LLC submitted a Form 144 notice to sell common stock of the issuer. The filing lists proposed sales of 13,625 shares (option granted 02/13/2017) and 8,998 shares (option granted 02/12/2018), with an indicated date of 02/18/2026.
This notice reports proposed dispositions under issuer-granted options and indicates cash settlement; timing and expected proceeds are not stated in the excerpt.
Johnson & Johnson insider plans Rule 144 stock sale. A holder has filed to sell 6,197 shares of Johnson & Johnson common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $1,508,299.61 and 2,409,898,936 shares reported outstanding.
The shares to be sold were acquired as compensation through restricted stock vesting from the issuer on several dates in 2025 and 2026, including 5,110 shares vesting on February 13, 2026. The seller represents they are not aware of undisclosed material adverse information about the company.
Shareholder James Swanson filed a Rule 144 notice to sell 20,521 Johnson & Johnson common shares with an aggregate market value of $4,980,510.40. The shares are planned to be sold on the NYSE around 02/17/2026 through Fidelity Brokerage Services LLC.
These shares were acquired on 02/17/2026 via options granted on 02/08/2021, with the 20,521 shares paid for in cash. Over the prior three months, Swanson sold 41,559 Johnson & Johnson common shares on 02/13/2026 for gross proceeds of $10,129,245.92.